SAN DIEGO--(BUSINESS WIRE)--Medical Marijuana Inc (OTC: MJNA) is pleased to announce that studies from foundations and universities around the world have proven Cannabidiol (CBD) as a therapeutic treatment for Multiple Sclerosis spasticity symptoms. Medical Marijuana Inc. through CannaBANK (www.mycannabank.com) has a patent pending on an extraction method in which they are able to extract Cannabidiol from Marijuana and Hemp. Cannabidiol extract is an easy way to improve currently accepted medical treatments efficacy. Cannabidiol (CBD) offers a feeling of clarity and greatly reduces anxiety without any of the psychoactive effects found from other properties within the Marijuana plant. It is imperative that this newly accepted legal substance be isolated from all other properties within the Marijuana plant to insure that all Multiple Sclerosis patients have access to its benefits.
“That’s what’s so amazing about our extract. It does not come with any of the psychoactive properties found within Marijuana. There is no ‘High’ feeling from Cannabidiol and it doesn’t even look like Marijuana! Drive with it in your car…. take it on the plane and feel comfortable knowing ITS LEGAL and it’s a nutritional necessity! For those of you in one of the 30 + States that don’t have access to Marijuana’s phenomenal medical attributes, YOU DO NOW! For those of you, who would not use Marijuana because of its stigma, be prepared to have a change of heart. This is something we should all be very excited about,” said Jared Berry, a CannaBANK Executive.
According to the National Multiple Sclerosis Society (www.nationalmssociety.org) MS affects 2.5 million people around the world. Many qualified companies are lining up in the hopes of a licensing agreement allowing them to use MJNA’s extraction process for a powerful solution to Multiple Sclerosis spasticity symptoms and, of course, a spike in profits. It won’t be long before a manufacturer and healthcare product distributor is chosen to help bring Cannabidiol to every Multiple Sclerosis patient.
“There is really no need for us to recreate the wheel. There are many dedicated, qualified companies that have developed great products. We are bringing this amazing compound to MS patients as soon as possible through established companies with distribution channels already in place,” Charlie Larsen, President of Medical Marijuana Inc., stated.
Resources and Abstracts:
United States National Library of Medicine (PubMed)
ABOUT MEDICAL MARIJUANA INC (OTC: MJNA)
Our mission is to be the world's premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate, invest in and purchase value-added sustainable companies, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, pay homage to the visionaries and activists of the past and present, and provide the platform from which the industry can emerge into a global sustainable economy for all. Medical Marijuana Inc recognizes the vast and unequaled opportunities that exist in the rapidly expanding hemp and medical marijuana industries. The scientific recognition of cannabis has brought legalized marijuana use to the forefront of mainstream discussion, thus opening the door for safe and lucrative investment opportunities.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana Inc to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration (FDA), products and statements are not intended to diagnose, treat, cure, or prevent any disease.